G-protein coupled receptor for histamine, primarily mediating gastric acid secretion. Predominantly expressed in the gastric mucosa, couples to G(s) G alpha proteins upon histamine binding, leading to activation of adenylate cyclase and increased intracellular cyclic AMP (cAMP) levels (PubMed:38647423, PubMed:39333117). This signaling cascade stimulates parietal cells to secrete hydrochloric acid, playing a key role in digestive physiology.
Also expressed in other tissues, including the heart and central nervous system, where it may contribute to cardiac stimulation and modulate neurotransmitter release (By similarity)
Interacts with GNAS
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to HRH2, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 2
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02551744 | Peptic Ulcer | Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers | NA | COMPLETED |
| NCT01408186 | Upper Gastrointestinal Bleeding | ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA | PHASE3 | COMPLETED |
| NCT02016820 | Clostridium Difficile Infection | Effect of Acid Suppression Medication on Pediatric Microbiome | NA | TERMINATED |
| NCT06313307 | Melasma | The Efficacy in Treatment of Facial Melasma Combined With Thulium 1927-nm Fractional Laser and Topical H2R Antagonist | NA | COMPLETED |
| NCT00001241 | Zollinger Ellison Syndrome | Treatment of Zollinger-Ellison Syndrome | N/A | COMPLETED |
| NCT03747991 | GERD, Dysbiosis | How Reflux Medications Affect the Microbiome of Infants | N/A | COMPLETED |
| NCT04540965 | Drug Interaction | Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects | PHASE1 | COMPLETED |
| NCT00120315 | Dyspepsia | Proton Pump Inhibitor Treatment Stop | PHASE4 | COMPLETED |
| NCT02418312 | Peptic Ulcer | Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer | NA | COMPLETED |